Difference in the effects of switching from candesartan to olmesartan or telmisartan to olmesartan in hypertensive patients with type 2 diabetes: the COTO study

about

Difference in the effects of switching from candesartan to olmesartan or telmisartan to olmesartan in hypertensive patients with type 2 diabetes: the COTO study

Item

http://www.wikidata.org/entity/Q37601188

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 17 February 2014

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Difference in the effects of s ...... ype 2 diabetes: the COTO study

@en

Difference in the effects of s ...... pe 2 diabetes: the COTO study.

@nl

type

Item

label

Difference in the effects of s ...... ype 2 diabetes: the COTO study

@en

Difference in the effects of s ...... pe 2 diabetes: the COTO study.

@nl

prefLabel

Difference in the effects of s ...... ype 2 diabetes: the COTO study

@en

Difference in the effects of s ...... pe 2 diabetes: the COTO study.

@nl

P1476

Difference in the effects of s ...... ype 2 diabetes: the COTO study

@en

P2093

Hiroyuki Daikuhara

http://www.w3.org/2001/XMLSchema#string

Kensaku Fukunaga

http://www.w3.org/2001/XMLSchema#string

Tomie Ohshima

http://www.w3.org/2001/XMLSchema#string

P2860

Telmisartan, ramipril, or both in patients at high risk for vascular events.

Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity.

Rationale, study design, baseline characteristics and blood pressure at 16 weeks in the HONEST Study.

Clinical and pharmacotherapeutic relevance of the double-chain domain of the angiotensin II type 1 receptor blocker olmesartan.

Effects of olmesartan on the renin-angiotensin-aldosterone system for patients with essential hypertension after cardiac surgery--investigation using a candesartan change-over study.

Effects of combination olmesartan medoxomil plus azelnidipine versus monotherapy with either agent on 24-hour ambulatory blood pressure and pulse rate in Japanese patients with essential hypertension: additional results from the REZALT study.

Effect of dosing time of angiotensin II receptor blockade titrated by self-measured blood pressure recordings on cardiorenal protection in hypertensives: the Japan Morning Surge-Target Organ Protection (J-TOP) study.

Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension.

Comparison of effects of angiotensin II receptor blocker on morning home blood pressure and cardiorenal protection between morning administration and evening administration in hypertensive patients: the COMPATIBLE study.

Blood pressure control in Japanese hypertensives with or without type 2 diabetes mellitus.

P304

219-226

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/DDDT.S53253

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P577

2014-02-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24600204

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes

P932

3933665

http://www.w3.org/2001/XMLSchema#string